Publications associées à Performance-enhancing substance

Improving SAM Requires Rethinking its Optimization Formulation

Volkan Cevher, Kimon Antonakopoulos, Thomas Michaelsen Pethick, Wanyun Xie, Fabian Ricardo Latorre Gomez

This paper rethinks Sharpness-Aware Minimization (SAM), which is originally formulated as a zero-sum game where the weights of a network and a bounded perturbation try to minimize/maximize, respectively, the same differentiable loss. We argue that SAM shou ...

2024

Renormalizing individual performance metrics for cultural heritage management of sports records

Orion B Penner

Individual performance metrics are commonly used to compare players from different eras. However, such cross-era comparison is often biased due to significant changes in success factors underlying player achievement rates (e.g. performance enhancing drugs ...

PERGAMON-ELSEVIER SCIENCE LTD2020

Glutamine-to-glutamate ratio in the nucleus accumbens predicts effort-based motivated performance in humans

Rolf Gruetter, Maria del Carmen Sandi Perez, Lijing Xin, Alina Veronika Irene Strasser, Gediminas Luksys

Substantial evidence implicates the nucleus accumbens in motivated performance, but very little is known about the neurochemical underpinnings of individual differences in motivation. Here, we applied 1H magnetic resonance spectroscopy (1H-MRS) at ultra-hi ...

2020

The diagnostic potential of multimodal neuroimaging measures in Parkinson's disease and atypical parkinsonism

Chang-Hyun Park

Introduction For the diagnosis of Parkinson's disease (PD) and atypical parkinsonism (AP) using neuroimaging, structural measures have been largely employed since structural abnormalities are most noticeable in the diseases. Functional abnormalities have b ...

2020

Direct and catalyst-free growth of vertically-stacked graphene-based structures for enhanced drug sensing

Giovanni De Micheli, Sandro Carrara, Nima Aliakbarinodehi

In this work, a complete study is carried out for the optimised, direct and catalyst-free growth of vertically-stacked graphene-based structures targeting at improved performance drug monitoring. The nanostructures, ultimately forming a honeycomb network o ...

IEEE2019

A Computational Approach for the Design of Epidural Electrical Spinal Cord Stimulation Strategies to Enable Locomotion after Spinal Cord Injury

Emanuele Formento

Spinal cord injury (SCI) is a major cause of paralysis with currently no effective treatment. Epidural electrical stimulation (EES) of the lumbar spinal cord has been shown to restore locomotion in animal models of SCI, but has not yet reached the same lev ...

EPFL2018

Fabrication and performance of 1.3-mu m 10-Gb/s CWDM wafer-fused VCSELs grown by MOVPE

Elyahou Kapon, Grigore Suruceanu, Alexandru Mereuta, Vladimir Iakovlev, Alexei Sirbu, Andrei Caliman, Zlatko Mickovic

Recent progress in the fabrication and performance of 1.3-mu m 10-Gb/s, low power consumption wafer-fused VCSELs grown by MOVPE under nitrogen atmosphere are presented and discussed. By optimization of the growth conditions and implementation of a cavity a ...

Elsevier Science Bv2015

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Andrea Pfeifer, Andreas Muhs

Scientists working in the field of Alzheimer's disease and, in particular, cognitive enhancers, are very productive. The review "Drugs interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs" was accepted in October 2012. In the l ...

Ios Press2014

Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery

Harm-Anton Klok

In the past decades, polymeric nanoparticles have emerged as a most promising and viable technology platform for targeted and controlled drug delivery. As vehicles, ideal nanoparticles are obliged to possess high drug loading levels, deliver drug to the sp ...

Elsevier Sci Ltd2013

Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

Andrea Pfeifer, Andreas Muhs

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, app ...

Ios Press2013

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Andrea Pfeifer, Andreas Muhs

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. Cognition refers to a capacity for information processing, app ...

Ios Press2013

Facilitation of AMPA receptor synaptic delivery as a molecular mechanism for cognitive enhancement

Maria del Carmen Sandi Perez, Erika Myrna Borcel Novoa, Lidia Alonso-Nanclares

Cell adhesion molecules and downstream growth factor-dependent signaling are critical for brain development and synaptic plasticity, and they have been linked to cognitive function in adult animals. We have previously developed a mimetic peptide (FGL) from ...

2012